1
|
Koh YC, Ho CT, Pan MH. Recent Advances in Health Benefits of Stilbenoids. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2021; 69:10036-10057. [PMID: 34460268 DOI: 10.1021/acs.jafc.1c03699] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Biological targeting or molecular targeting is the main strategy in drug development and disease prevention. However, the problem of "off-targets" cannot be neglected. Naturally derived drugs are preferred over synthetic compounds in pharmaceutical markets, and the main goals are high effectiveness, lower cost, and fewer side effects. Single-target drug binding may be the major cause of failure, as the pathogenesis of diseases is predominantly multifactorial. Naturally derived drugs are advantageous because they are expected to have multitarget effects, but not off-targets, in disease prevention or therapeutic actions. The capability of phytochemicals to modulate molecular signals in numerous diseases has been widely discussed. Among them, stilbenoids, especially resveratrol, have been well-studied, along with their potential molecular targets, including AMPK, Sirt1, NF-κB, PKC, Nrf2, and PPARs. The analogues of resveratrol, pterostilbene, and hydroxylated-pterostilbene may have similar, if not more, potential biological targeting effects compared with their original counterpart. Furthermore, new targets that have been discussed in recent studies are reviewed in this paper.
Collapse
Affiliation(s)
- Yen-Chun Koh
- Institute of Food Sciences and Technology, National Taiwan University, Taipei 10617, Taiwan
| | - Chi-Tang Ho
- Department of Food Science, Rutgers University, New Brunswick, New Jersey 08901, United States
| | - Min-Hsiung Pan
- Institute of Food Sciences and Technology, National Taiwan University, Taipei 10617, Taiwan
- Department of Medical Research, China Medical University Hospital, China Medical University, Taichung City, Taiwan 404
- Department of Health and Nutrition Biotechnology, Asia University, Taichung City, Taiwan 413
| |
Collapse
|
3
|
Castelli T, Russo GI, Reale G, Privitera S, Chisari M, Fragalà E, Favilla V, Cimino S, Morgia G. Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review. Int Braz J Urol 2017; 42:422-30. [PMID: 27286103 PMCID: PMC4920557 DOI: 10.1590/s1677-5538.ibju.2015.0095] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 06/12/2015] [Indexed: 11/22/2022] Open
Abstract
Benign prostatic hyperplasia and prostate cancer are two common urological diseases of the elderly. Scientific community has always looked for a link that could explain the correlation between the two diseases and the role of chronic inflammation in the pathogenesis of BPH and PCa. As shown by the reports of the two diseases relationship with oxidative stress and metabolic syndrome, the use of compounds with antioxidant action could therefore affect both the symptoms and their onset. Polyphenols appear to act not only against oxidative stress but also at different levels. The aim of this review is to evaluate the role of the most important polyphenols on these two urological diseases. As antioxidants these compounds seems to have a direct action on the cell cycle and hormone function, important for both prostate cancer and BPH. Despite a large number of articles about the relationship of the polyphenols with prostate cancer, very little evidence exists for BPH. Additional clinical trials or meta-analysis are necessary on this topic.
Collapse
Affiliation(s)
- Tommaso Castelli
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Giorgio Ivan Russo
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Giulio Reale
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Salvatore Privitera
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Mario Chisari
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Eugenia Fragalà
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Vincenzo Favilla
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Sebastiano Cimino
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| | - Giuseppe Morgia
- Dipartimento di Urologia, Facoltà di Medicina Policlinico, Università di Catania, Italia
| |
Collapse
|
4
|
Vancauwenberghe E, Noyer L, Derouiche S, Lemonnier L, Gosset P, Sadofsky LR, Mariot P, Warnier M, Bokhobza A, Slomianny C, Mauroy B, Bonnal JL, Dewailly E, Delcourt P, Allart L, Desruelles E, Prevarskaya N, Roudbaraki M. Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts (CAF). Mol Carcinog 2017; 56:1851-1867. [PMID: 28277613 DOI: 10.1002/mc.22642] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 02/10/2017] [Accepted: 03/03/2017] [Indexed: 12/18/2022]
Abstract
Previous studies showed the effects of resveratrol (RES) on several cancer cells, including prostate cancer (PCa) cell apoptosis without taking into consideration the impact of the tumor microenvironment (TME). The TME is composed of cancer cells, endothelial cells, blood cells, and cancer-associated fibroblasts (CAF), the main source of growth factors. The latter cells might modify in the TME the impact of RES on tumor cells via secreted factors. Recent data clearly show the impact of CAF on cancer cells apoptosis resistance via secreted factors. However, the effects of RES on PCa CAF have not been studied so far. We have investigated here for the first time the effects of RES on the physiology of PCa CAF in the context of TME. Using a prostate cancer CAF cell line and primary cultures of CAF from prostate cancers, we show that RES activates the N-terminal mutated Transient Receptor Potential Ankyrin 1 (TRPA1) channel leading to an increase in intracellular calcium concentration and the expression and secretion of growth factors (HGF and VEGF) without inducing apoptosis in these cells. Interestingly, in the present work, we also show that when the prostate cancer cells were co-cultured with CAF, the RES-induced cancer cell apoptosis was reduced by 40%, an apoptosis reduction canceled in the presence of the TRPA1 channel inhibitors. The present work highlights CAF TRPA1 ion channels as a target for RES and the importance of the channel in the epithelial-stromal crosstalk in the TME leading to resistance to the RES-induced apoptosis.
Collapse
Affiliation(s)
- Eric Vancauwenberghe
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Lucile Noyer
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Sandra Derouiche
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Loïc Lemonnier
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Pierre Gosset
- Faculté Libre de Médecine, Laboratoire d'Anatomie et de Cytologie Pathologique du groupement hospitalier de l'Institut Catholique de Lille, Lille, France
| | - Laura R Sadofsky
- Cardiovascular and Respiratory Studies, The University of Hull, Castle Hill Hospital, Cottingham, United Kingdom
| | - Pascal Mariot
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Marine Warnier
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Alexandre Bokhobza
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Christian Slomianny
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Brigitte Mauroy
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Service d'Urologie de l'hôpital St-Philibert, Lille, France
| | - Jean-Louis Bonnal
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Service d'Urologie de l'hôpital St-Philibert, Lille, France
| | - Etienne Dewailly
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Philippe Delcourt
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Laurent Allart
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Emilie Desruelles
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Natalia Prevarskaya
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| | - Morad Roudbaraki
- Univ. Lille, Inserm, U1003-PHYCEL-Physiologie Cellulaire, Equipe labellisée par la Ligue Nationale contre le cancer, Villeneuve d'Ascq, Lille, France.,Laboratory of Excellence, Ion Channels Science and Therapeutics, Université Lille I Sciences et Technologies, Villeneuve d'Ascq, France
| |
Collapse
|
5
|
Kim CW, Hwang KA, Choi KC. Anti-metastatic potential of resveratrol and its metabolites by the inhibition of epithelial-mesenchymal transition, migration, and invasion of malignant cancer cells. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2016; 23:1787-1796. [PMID: 27912881 DOI: 10.1016/j.phymed.2016.10.016] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Revised: 10/19/2016] [Accepted: 10/26/2016] [Indexed: 05/15/2023]
Abstract
BACKGROUND Increased epithelial-mesenchymal transition (EMT) and cell migration and invasion abilities of cancer cells play important roles in the metastatic process of cancer. Resveratrol is a stilbenoid, a type of natural polyphenol found in the skin of grapes, berries, and peanuts. A number of experiments have examined resveratrol's ability to target diverse pathways associated with carcinogenesis and cancer progression. PURPOSE This article aims to present updated overview of the knowledge that resveratrol and its metabolites or analogs have the potential to inhibit metastasis of cancer via affecting many signaling pathways related with EMT, cancer migration, and invasion in diverse organs of the body. CHAPTERS This article starts with a short introduction describing diverse beneficial effects of resveratrol including cancer prevention and the aim of the present study. To address the effects of resveratrol on cancer metastasis, mechanisms of EMT, migration, invasion, and their relevance with cancer metastasis, anti-metastatic effects of resveratrol through EMT-related signaling pathways and inhibitory effects of resveratrol on migration and invasion are highlighted. In addition, anti-metastatic potential of resveratrol metabolites and analogs is addressed. CONCLUSION Resveratrol was demonstrated to turn back the EMT process induced by diverse signaling pathways in several cellular and animal cancer models. In addition, resveratrol can exert chemopreventive efficacies on migration and invasion of cancer cells by inhibiting the related pathways and target molecules. Although these findings display the anti-metastatic potential of resveratrol, more patient-oriented clinical studies demonstrating the marked efficacies of resveratrol in humans are still needed.
Collapse
Affiliation(s)
- Cho-Won Kim
- Laboratory of Biochemistry and Immunology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
| | - Kyung-A Hwang
- Laboratory of Biochemistry and Immunology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea.
| | - Kyung-Chul Choi
- Laboratory of Biochemistry and Immunology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea.
| |
Collapse
|